Different responses to chronic somatostatin analogues in patients with central hyperthyroidism
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Summary: Objective Central hyperthyroidism is mainly due to two different causes, TSH‐secreting pituitary adenoma (TSH‐oma) and resistance to thyroid hormone in its pituitary variant, i.e. patients presenting with signs and symptoms of hyperthyroidism (PRTH). Because therapeutic approach and the clinical follow‐up are extremely different in these two disorders, a correct differential diagnosis is mandatory. Unfortunately, no definite pathognomonic tool is presently available and an extensive biochemical and instrumental workup is frequently needed in order to reach the correct diagnosis. Aim of the present study was to investigate the use of somatostatin analogues in the differential diagnosis between TSH‐omas and PRTH, as well as the possible treatment of PRTH with these analogues. Design and Patients Eight patients with TSH‐oma and four with PRTH underwent the acute test with somatostatin analogue Octreotide (0·1 mg subcutaneously), as well as long‐acting Octreotide‐LAR (30 mg intramuscularly every 28 days) for two months. Measurements Serum TSH, FT3 and FT4 were evaluated in basal condition, at time 0 and every hour for 6 h during acute test, and every 15 days for 2 months during chronic treatment. Results During acute test, in both patients with PRTH and TSH‐oma, a similar reduction in immunoreactive TSH and FT3 levels was observed, while no variations were found in FT4 concentrations. In contrast, during the administration of Octreotide‐LAR, no significant variations of all tested parameters were observed in PRTH group, whereas FT3 and FT4 concentrations normalized or presented a significant reduction (> 30% of pretreatment values) in seven of eight patients with TSH‐oma, despite minor variation of immunoreactive TSH levels. Conclusions Chronic administration of long‐acting somatostatin analogues in patients with central hyperthyroidism caused a marked decrease of FT3 and FT4 levels in all patients but one with TSH‐oma, while patients with PRTH did not respond at all. Thus, administration of long acting somatostatin analogues for at least 2 months can be useful in the differential diagnosis in problematic cases of central hyperthyroidism. Furthermore, the present findings exclude the possibility of a beneficial effect of chronic administration of somatostatin analogues in controlling thyrotoxic symptoms in PRTH patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Variable biological activity of thyroid-stimulating hormone
Beck-Peccoz, P., & Persani, L. (1994) · European Journal of Endocrinology · doi:10.1530/eje.0.1310331 · Cited by 116
Self-citation
Cited by
Beck-Peccoz, P., Lania, A., Beckers, A., Chatterjee, K., & Wemeau, J.-L. (2013) · European Thyroid Journal · doi:10.1159/000351007 · Cited by 283
Self-citationPitfalls in the measurement and interpretation of thyroid function tests
Koulouri, O., Moran, C., Halsall, D., Chatterjee, K., & Gurnell, M. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.10.003 · Cited by 282
Drugs that suppress TSH or cause central hypothyroidism
Haugen, B. R. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.08.003 · Cited by 252
“Haugen / Best Practice & Research Clinical Endocrinology & Metabolism 23 (2009) 793–800 798”
BackgroundInfluentialA 2019 update on TSH-secreting pituitary adenomas
Beck-Peccoz, P., Giavoli, C., & Lania, A. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01066-x · Cited by 111
Self-citationThyrotropin-Secreting Pituitary Adenomas: Outcome of Pituitary Surgery and Irradiation
Malchiodi, E., Profka, E., Ferrante, E., Sala, E., Verrua, E., Campi, I., Lania, A. G., Arosio, M., Locatelli, M., Mortini, P., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4376 · Cited by 89
Self-citation
Metadata
- Authors
- Mannavola, D., Persani, L., Vannucchi, G., Zanardelli, M., Fugazzola, L., Verga, U., Facchetti, M., & Beck‐Peccoz, P.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2004-12-23
- Volume
- 62
- Issue
- 2
- Pages
- 176-181
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2084388049
- Cited by
- 104
- References
- 1
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Different responses to chronic somatostatin analogues in patients with central hyperthyroidism. https://app.cochat.ai/papers/10.1111/j.1365-2265.2004.02192.x
- The paper
- Mannavola, D., Persani, L., Vannucchi, G., Zanardelli, M., Fugazzola, L., Verga, U., Facchetti, M., & Beck‐Peccoz, P. (2005). Different responses to chronic somatostatin analogues in patients with central hyperthyroidism. Clinical Endocrinology. https://doi.org/10.1111/j.1365-2265.2004.02192.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.